You have 9 free searches left this month | for more free features.

B-cell Acute Lymphoblastic Leukemia

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • QH103 Cell Injection
  • +2 more
  • Hefei, Anhui, China
    Anhui Provincial Hospital
Sep 21, 2023

B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)

Recruiting
  • B-Cell Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia
  • Tampa, Florida
    Moffitt Cancer Center
Nov 28, 2023

Refractory B-cell Acute Lymphoblastic Leukemia Trial in Houston (Mosunetuzumab)

Not yet recruiting
  • Refractory B-cell Acute Lymphoblastic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2023

B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • (no location specified)
Oct 10, 2023

B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • HY004
  • +2 more
  • (no location specified)
Aug 18, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Leukemia, Acute Lymphoblastic Leukemia Trial in New York (gene-modified T cells targeted)

Active, not recruiting
  • Leukemia
  • Acute Lymphoblastic Leukemia
  • gene-modified T cells targeted
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 1, 2023

B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)

Recruiting
  • B-Cell Non Hodgkin Lymphoma
  • B-Cell Acute Lymphoblastic Leukemia
  • anti-CD19 CAR T-cells
  • Hanoi, Vietnam
    Vinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023

Patients Who Received Inotuzumab Ozogamicin for B-cell ALL That

Not yet recruiting
  • Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
  • Inotuzumab Ozogamicin
  • (no location specified)
Nov 3, 2022

B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (U-CAR-T Cells (LstCAR019))

Withdrawn
  • B-cell Acute Lymphoblastic Leukemia
  • B-ALL
  • U-CAR-T Cells (LstCAR019)
  • Kunming, Yunnan, China
    Kunming Hope of Health Hospital
Nov 27, 2022

B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (UCAR-T Cells)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-ALL
  • UCAR-T Cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Dec 7, 2022

Acute Lymphocytic Leukemia Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Recruiting
  • Acute Lymphocytic Leukemia
  • CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
  • Tianjin, Tianjin, China
    Hematology Hospital, Chinese Academy of Medical Sciences
Feb 5, 2023

Acute Lymphoblastic Leukemia Trial in Tianjin (CN201)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Oct 14, 2022

B-cell Acute Lymphoblastic Leukemia Trial (single dose of CNCT19)

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • single dose of CNCT19
  • (no location specified)
Dec 19, 2022

Leukemia, Lymphoid Trial in Chengdu (blinatumomab)

Recruiting
  • Leukemia, Lymphoid
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Oct 27, 2023

B-cell Acute Lymphoblastic Leukemia Trial in Nanchang (Human CD19 Targeted DASH CAR-T Cells Injection)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • Human CD19 Targeted DASH CAR-T Cells Injection
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Dec 13, 2022

B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma Trial (Cyclophosphamide, Vincristine, Dexamethasone)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • B Lymphoblastic Lymphoma
  • (no location specified)
Aug 2, 2022

Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive Trial in Monrovia,

Recruiting
  • Blasts 5 Percent or More of Bone Marrow Nucleated Cells
  • +4 more
  • ADCT-602
  • Monrovia, California
  • +1 more
Dec 7, 2022

Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited Trial (ThisCART19A, Fludarabine Oral Tablet, Cyclophosphamide)

Not yet recruiting
  • Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
  • (no location specified)
Oct 8, 2022

CAR, Refractory Acute Lymphoblastic Leukemia, Relapsed Adult ALL Trial in Suzhou (Treatment)

Recruiting
  • CAR
  • +2 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 27, 2022

B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma Trial (Autologous Humanized CD19-Directed Chimeric

Not yet recruiting
  • B Cell Acute Lymphoblastic Leukemia (B-ALL)
  • B Lineage Lymphoblastic Lymphoma
  • Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
  • (no location specified)
Jul 27, 2022

B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Unspecified Trial in Guangzhou, Guanzhou (CD19 CAR T-Cell(CAT19T2))

Not yet recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-Cell Lymphoma, Unspecified
  • CD19 CAR T-Cell(CAT19T2)
  • Guangzhou, Guangdong, China
  • +1 more
Nov 4, 2022

B-cell Acute Lymphoblastic Leukemia Trial in Suzhou (Blinatumomab, Conventional therapy)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • Suzhou, Jiangsu, China
    The first affiliated hospital of Soochow University
Sep 26, 2022

Leukemia Trial in Shenyang (IM19 CAR-T cells)

Recruiting
  • Leukemia
  • IM19 CAR-T cells
  • Shenyang, Liaoning, China
    First Hospital of China Medical University
Jul 27, 2022

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Trial in Tianjin (CD19-CD22 CAR-T cells)

Active, not recruiting
  • Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
  • CD19-CD22 CAR-T cells
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 2, 2022